1. New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
- Author
-
V F Semiglazov, P. Krivorotko, Gulfiya Midhatovna Teletaeva, Paltuev Rm, R V Donskikh, Tkachenko Ev, V. A. Klyuge, T Yu Semiglazova, G.A. Dashyan, and Vladislav Semiglazov
- Subjects
Eribulin Mesylate ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Advanced breast ,overall survival ,Population ,lcsh:RC254-282 ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,law ,triple negative subtype ,Internal medicine ,medicine ,Overall survival ,education ,skin and connective tissue diseases ,eribulin ,Chemotherapy ,education.field_of_study ,business.industry ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Metastatic breast cancer ,chemistry ,quality of life ,metastatic breast cancer ,business ,Eribulin - Abstract
Since 1990-s the efficiency of treatment of patients with metastatic/advanced breast cancer (MBC) was started to evaluate not only by overall survival but also by quality of life which is characterized by physical, social, mental and emotional condition of the patient. As there are no standards of system treatment for MBC after anthracyclines and taxanes, choice of further tactics was based on separate randomized trials and own intuition of the oncologist until recently. Eribulin mesylate (eribulin) became the first chemotherapy agent, confirmed to be effective in two large randomized trials: in first of them a significant increase of overall survival and the preservation of quality of life were shown in population of patients with MBC progressing after treatment including anthracycline antibiotics and taxanes. In second trial advantage of the drug was registered in patients with triple negative and luminal B HER2-negative MBC subtypes.
- Published
- 2016